Genmab — September 2020
-
fiercebiotech - ESMO: Seattle Genetics' ADC candidate curbs hard-to-treat cervical cancer - https://www.fiercebiotech.com/biotech/esmo-seattle-genetics-adc-curbs-hard-to-treat-cervical-cancer
-
Det giver jo alt sammen til at lave en robust forretning, med mange ben at stå på og det er jo ikke det nemmeste i verden de udvikler på - det kunne også have været et hard stop uden signifikant effekt og 0 værdi i det område.
-
-0,16% er til at holde til på en dag hvor DAX futter
er neden med 4,5% -
Novo også drønstærk i dag.
-
.@rcoledude presents results from the InnovaTV trial of tisotumab vedotin. There was a 24% response rate in patients w/ recurrent #cervical cancer, >50% of patients had stable disease beyond 6 months! https://twitter.com/shannonwestin/status/1308062372075122688?s=21
-
https://twitter.com/seattlegenetics/status/1308048587255771136?s=21 Annonce på Twitter siger 13.800+ nye cervical patienter i US årligt. Så stort marked og de har vel også åbnet for at tiso kunne blive blockbuster. Vi har vel heller ikke set weekly behandling, som forventes med bedre resultat.
-
Yes, Japan is very important, they don‘t give their teenage girls the hpv vaccine
-
-
God morgen.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind